作　　者： (赵枭卿）; (冷静）;

机构地区： 广西医科大学基础医学院免疫学教研室,南宁530000

出　　处： 《免疫学杂志》 2017年第9期813-818,共6页

摘　　要： Toll样受体8(Toll-like receptor 8,TLR8)激动剂是一种小分子免疫应答调节剂,主要包括天然核苷类化合物和人工合成的化合物,可以有效激活天然免疫并引起适应性免疫应答,具有有效的抗感染、抗肿瘤等性能,并在新生儿免疫中起到独特的作用。因此,有潜力作为疫苗佐剂或者独立的免疫治疗。本文就TLR8受体激动剂在各种临床前及临床免疫治疗中的研究进展作一综述,进而为TLR8为靶点的抗感染、自身免疫性疾病、肿瘤等疾病的治疗提供参考。 Small molecule Toll-like receptor 8 agonists mainly including natural nucleoside compounds and synthetic compounds, can effectively activate the innate immune and adaptive immune response resulting in effective anti-infection, anti-tumor response and plays a unique role in neonatal immune. Thus these agonists can be used as excellent adjuvants and independent regents in immunotherapy for various diseases. This review will highlight the preclinical and clinical studies that indicate promise for TLR8 ligands as vaccine adjuvants and independent immunotherapy thus far, then provide a reference for TLR8 as targets for immunotherapy such as infection, autoimmune disease and tumor treatment.

关 键 词： 激动剂 免疫治疗 佐剂